MIRA INFORM REPORT
|
Report Date : |
28.09.2011 |
IDENTIFICATION DETAILS
|
Name : |
CHROMOGENEX TECHNOLOGIES LTD. |
|
|
|
|
Registered Office : |
Unit 1 & 2 Heol Rhosyn, Parc Dafen, Llanelli, SA14 8QG |
|
|
|
|
Country : |
United Kingdom |
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
13.05.1992 |
|
|
|
|
Com. Reg. No.: |
02714095 |
|
|
|
|
Legal Form : |
Private Subsidiary |
|
|
|
|
Line of Business : |
developer and manufacturer
of laser and intense-pulsed light systems |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Moderate |
|
|
|
|
Payment
Behaviour : |
Unknown |
|
|
|
|
Litigation : |
--- |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
|
|
|
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
Chromogenex Technologies Ltd.
Unit 1
2
Heol Rhosyn Dafen Ind Pk Dafen
Llanelli, SA14 8QG
United Kingdom
Tel: 01554755444
Fax: 01554755333
Web: www.chromogenex.com
Synthesis
Employees: 32
Company Type: Private Subsidiary
Corporate Family: 3
Companies
Ultimate Parent: Chromogenex Holdings Ltd.
Quoted Status: Non-quoted Company
Incorporation Date:
13-May-1992
Auditor: Bevan And Buckland
Financials in: USD
(Millions)
Fiscal Year End:
31-Dec-2010
Reporting Currency: British
Pound Sterling
Annual Sales: 5.3
1
Net Income: 0.8
Total Assets: 3.4
Business Description
Chromogenex
Technologies Ltd. is a developer and manufacturer of laser and intense-pulsed
light systems. The company provides laser and light technology for various
applications, such as hair removal, skin rejuvenation and wrinkle reduction. It
provides the Regenlite pulsed dye laser used to treat various skin diseases,
including acne, psoriasis and vascular lesions. The company also offers
products used for permanent hair reduction and the removal of benign cutaneous
pigmented lesions. It additionally manufactures systems used to assist patients
to quit smoking. The company also provides various systems to exfoliate and
smoothen uneven skin and reduce fine lines, discolouration, spots and
blackheads. In addition, it provides a range of customer support services.
Industry
Industry Medical Equipment and Supplies
ANZSIC 2006: 2412 - Medical and
Surgical Equipment Manufacturing
NACE 2002: 3310 - Manufacture
of medical and surgical equipment and orthopaedic appliances
NAICS 2002: 33911 - Medical
Equipment and Supplies Manufacturing
UK SIC 2003: 3310 - Manufacture
of medical and surgical equipment and orthopaedic appliances
US SIC 1987: 384 - Surgical,
Medical, and Dental Instruments and Apparatus
Key Executives
|
Name |
Title |
|
David Gareth Morgan |
Secretary |
|
Peter William Mcguinness |
Director |
|
Kevin Donald Williams |
Director |
News
|
Title |
Date |
|
Research
and Markets: 'Aesthetic Lasers and Energy Devices: Global Market Briefing to
2017' - Intense competition expected to result in a reducing price trend |
29-Jul-2011 |
|
Trio of
leading businesses land our top awards |
8-Jul-2011 |
Financial Summary
|
FYE: 31-Dec-2010 |
USD (mil) |
||||||||||||||||||
|
|||||||||||||||||||
Registered No.(UK): 02714095
1 - Profit & Loss Item Exchange Rate: USD 1 = GBP 0.6475734
2 - Balance Sheet Item Exchange Rate: USD 1 = GBP 0.6387123
Corporate Overview
Location
Unit 1
2
Heol Rhosyn Dafen Ind Pk Dafen
Llanelli, SA14 8QG
Carmarthenshire County
United Kingdom
Tel: 01554755444
Fax: 01554755333
Web: www.chromogenex.com
Sales GBP(mil): 3.4
Assets GBP(mil): 2.2
Employees: 32
Fiscal Year End: 31-Dec-2010
Industry: Medical Equipment and Supplies
Registered
Address:
Unit 1 & 2 Heol Rhosyn
Parc Dafen
Llanelli, SA14 8QG
United Kingdom
Incorporation Date: 13-May-1992
Company Type: Private Subsidiary
Quoted Status: Not Quoted
Registered No.(UK): 02714095
Director: Peter William
Mcguinness
Contents
· Industry Codes
· Business Description
· Financial Data
· Key Corporate Relationships
· Gazette Status
Industry Codes
ANZSIC 2006 Codes:
2412 - Medical and Surgical Equipment Manufacturing
NACE 2002 Codes:
3310 - Manufacture of medical and surgical equipment and
orthopaedic appliances
NAICS 2002 Codes:
33911 - Medical Equipment and Supplies Manufacturing
US SIC 1987:
384 - Surgical, Medical, and Dental Instruments and Apparatus
UK SIC 2003:
3310 - Manufacture of medical and surgical equipment and
orthopaedic appliances
Business
Description
Chromogenex
Technologies Ltd. is a developer and manufacturer of laser and intense-pulsed
light systems. The company provides laser and light technology for various
applications, such as hair removal, skin rejuvenation and wrinkle reduction. It
provides the Regenlite pulsed dye laser used to treat various skin diseases,
including acne, psoriasis and vascular lesions. The company also offers
products used for permanent hair reduction and the removal of benign cutaneous
pigmented lesions. It additionally manufactures systems used to assist patients
to quit smoking. The company also provides various systems to exfoliate and
smoothen uneven skin and reduce fine lines, discolouration, spots and
blackheads. In addition, it provides a range of customer support services.
More Business
Descriptions
Chromogenex
Technologies Ltd., based in Llanelli, Dyfed, is the parent company to
EUPhotonics Ltd., a manufacturer of lasers for the medical and industrial
sector. It operates out of a 10,000-square feet factory in the South Wales
region of the United Kingdom. The company also has offices in London.
EUPhotonics has grown from a manufacturing and repair service to being a
company with expertise in research, design and development, software,
purchasing, logistics, manufacturing, functional testing, sales, customer
support and service. It operates a system that meets the European Medical
Device Directives and United States Food and Drug Administration current good
manufacturing practice. The company has distributed its devices throughout the
world while meeting all product, system and regulatory requirements. Products
made by the company include Chromolite, an intense pulse light device using
EUPhotonics own smartlite treatment technology; NLite V, a non-surgical laser
treatment; and SP Dermal Infusion, which provides both non-invasive exfoliation
and delivery of skin-specific topical solutions. (Updated by OneSource
Information Services)
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Corporate
Family |
Corporate
Structure News: |
|
|
|
|
Total Corporate Family Members: 3 |
|
|
|
|
|
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
Source |
|
Parent |
Llanelli |
United Kingdom |
|
|
|
RM |
|
|
Subsidiary |
Llanelli |
United Kingdom |
Medical Equipment and Supplies |
5.3 |
32 |
EXP |
|
|
Subsidiary |
Llanelli |
United Kingdom |
Business Services |
0.4 |
|
EXP |
Executive report
|
Board of
Directors |
|
|
|
|
|||
|
Director |
Director/Board Member |
|
|||
|
Director |
Director/Board Member |
|
|
Executives |
|
|
|
|
||||
|
Secretary |
Company Secretary |
|
Directors and Shareholders Report
|
Main Office
Address: |
Tel: 01554755444 |
Annual Return Date: 30 Apr 2011 |
|
Individual Directors |
|||||||
|
|
|||||||
|
Name |
Status |
DOB |
Filed Address |
Appointment Date |
Resignation Date |
Summary of
Directorships |
|
|
Current |
23 Nov 1963 |
Units 1 And 2, Heol Rhosyn Parc Dafen Llanelli, |
10 Feb 2011 |
NA |
Current:4 |
|
|
|
Current |
15 Mar 1960 |
69 Southward Lane, Newton, |
10 Feb 2011 |
NA |
Current:8 |
|
|
|
Current |
25 Jan 1966 |
Unit 1 & 2 Heol Rhosyn, Parc Dafen, |
14 Feb 2003 |
NA |
Current:5 |
|
|
|
Previous |
13 Feb 1960 |
Highfield, Gors Road Upper Tumble, |
12 Nov 1997 |
11 May 2000 |
Current:3 |
|
|
|
Previous |
02 Dec 1942 |
Wych Elm, Fishery Road, |
NA |
04 Jun 1996 |
Current:0 |
|
|
|
Previous |
09 Jul 1956 |
45 Bridgeport, Newport Coast, |
13 May 2000 |
14 Nov 2002 |
Current:0 |
|
|
|
Previous |
02 Dec 1942 |
Calzada Tlalpan 2021, 04040 Mexo Df, |
13 May 2000 |
03 Sep 2001 |
Current:0 |
|
|
|
Previous |
09 Jun 1951 |
33 Llythrid Avenue, Uplands, |
05 Sep 1997 |
03 Jul 1998 |
Current:0 |
|
|
|
Previous |
16 Jan 1948 |
12 Georgian Way, |
01 Jul 1994 |
24 Jan 1995 |
Current:7 |
|
|
|
Previous |
04 Jun 1938 |
1015 Highway, 337 Old Bronson Road, |
04 Jun 1996 |
18 Aug 1998 |
Current:0 |
|
|
|
Previous |
09 Mar 1943 |
Foxhill Farm, Broad Haven, |
06 Apr 1993 |
30 Jun 1995 |
Current:2 |
|
|
|
Previous |
30 Jul 1941 |
Bourne Bank, Hedsor Road, |
NA |
11 Apr 1995 |
Current:0 |
|
|
|
Previous |
09 Jan 1959 |
10 St Mellion Close, Monkton Park, |
01 Aug 1996 |
22 Jun 1998 |
Current:11 |
|
|
|
Previous |
26 Sep 1942 |
Post Box N215, |
13 May 2000 |
13 Feb 2003 |
Current:0 |
|
|
|
Previous |
19 Nov 1953 |
11 Plas Road, Rhos Pontardawe, |
01 Mar 1993 |
14 Feb 2003 |
Current:1 |
|
|
|
Previous |
31 Jan 1973 |
25261 Vealsquez Road, |
05 Sep 2001 |
14 Feb 2003 |
Current:0 |
|
|
|
Previous |
23 Jan 1948 |
Po Box 675493, |
05 Sep 2001 |
14 Nov 2002 |
Current:0 |
|
|
|
Previous |
23 Jun 1961 |
31 New Dawn, |
13 May 2000 |
03 Sep 2001 |
Current:0 |
|
|
|
|
|
||||||
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
Corporate Directors |
|
|
|
There are no corporate directors for this company. |
|
|
|
Individual Secretaries |
|||||||
|
|
|||||||
|
Name |
Status |
DOB |
Filed Address |
Appointment Date |
Resignation Date |
Summary of Directorships |
|
|
Current |
15 Mar 1960 |
69 Southward Lane, Newton, |
26 Jul 2005 |
NA |
Current:8 |
|
|
|
Previous |
16 Dec 1955 |
8 Caesars Gate, |
14 Feb 2003 |
26 Jul 2005 |
Current:2 |
|
|
|
Previous |
02 Dec 1942 |
Wych Elm, Fishery Road, |
NA |
01 Mar 1993 |
Current:0 |
|
|
|
Previous |
24 Oct 1970 |
22 Clos Leighton Davies, Gowerton, |
30 Mar 1993 |
14 Feb 2003 |
Current:0 |
|
|
|
|
|
||||||
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
Corporate Secretaries |
|
|
|
There are no corporate secretaries for this company. |
|
|
|
Individual Shareholders |
||||||
|
|
||||||
|
There are no individual shareholders for this company. |
||||||
|
|
||||||
|
|
||||||
|
|
|
|
|
|
|
|
|
Corporate Shareholders |
|||||||
|
|
|||||||
|
Company Name |
Registration Number |
Share Details |
Share Type |
# of Shares |
Share Price (GBP) |
Share Value (GBP) |
% of Total Shares |
|
07496824 |
4794695 Ordinary GBP 0.10 |
Ordinary |
4,794,695 |
0.10 |
479,469.50 |
91.48 |
|
|
07496824 |
446600 Deferred GBP 0.10 |
Deferred |
446,600 |
0.10 |
44,660.00 |
8.52 |
|
|
|
|||||||
Press clippings
Research and
Markets: 'Aesthetic Lasers and Energy Devices: Global Market Briefing to 2017'
- Intense competition expected to result in a reducing price trend
Business Wire: 29
July 2011
[What follows is
the full text of the news story.]
DUBLIN--(BUSINESS WIRE)-- Research and Markets
(http://www.researchandmarkets.com/research/4e26d7/aesthetic_lasers_a) has
announced the addition of GlobalData's new report "Aesthetic Lasers and
Energy Devices - Global Market Briefing to 2017" to their offering.
GlobalData's new
report, Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017
provides key data, information and analysis on the global aesthetic lasers and
energy devices market. The report provides market landscape, competitive
landscape and market trends information on the aesthetic lasers and energy
devices market. The report provides comprehensive information on the key trends
affecting the market, and key analytical content on the market dynamics. The
report also reviews the competitive landscape and technology offerings.
The Global
Aesthetic Lasers and Energy Devices Market is Forecast to Reach $2.4 billion by
2017
The global market
for aesthetic lasers and energy devices was valued at $1.1 billion in 2010, and
is forecast to reach $2.4 billion in 2017, at a CAGR of 13%. The market is
mainly driven by increasing awareness among patients about the appropriate
procedures available to them. This is supplemented by many factors from the
supply side.
The increasing
number of players in the aesthetic lasers and energy devices market has led to
intense competition between the companies. This is expected to result in a
reducing price trend in the near future, in turn increasing affordability for
the patients. Non-invasive devices will be the fastest growing category in the
aesthetic lasers and energy devices market.
Non-invasive
devices are driven by the benefits associated with them, such as minimal
downtime, cost effectiveness and better efficacy in fat reduction. Emerging
economies will be the focal point for the new entrants and existing companies
in this market. Emerging markets have huge potential for body contouring and
skin rejuvenation procedures due to rising income levels and increasing
affordability. Recovery of the developed economies is one of the key factors
for the growth of aesthetic lasers and energy devices. In 2010, revenue from
aesthetic lasers and energy devices from the US and Europe grew by about 30% to
40% over 2009.
Companies Mentioned:
Syneron Medical
Lumenis Ltd
Cynosure, Inc
Palomar Medical Technologies
Sound Surgical Technologies LLC
Fotona
Solta Medical, Inc.
Cutera, Inc
Alma Lasers, Ltd.
Chromogenex Technologies LTD
Pollogen, Ltd.
Invasix Ltd.
Ultrashape Ltd.
Lutronic, Inc.
Zeltiq Aesthetics
Medicis Pharmaceutical Corporation
Erchonia, Inc.
For more information visit
http://www.researchandmarkets.com/research/4e26d7/aesthetic_lasers_a
Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Annual Profit & Loss
Financials in: USD
(mil)
Except for share
items (millions) and per share items (actual units)
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
31-Dec-2006 |
|
Period Length |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate
(Period Average) |
0.647573 |
0.641508 |
0.545576 |
0.499878 |
0.543438 |
|
Consolidated |
No |
No |
No |
No |
No |
|
|
|
|
|
|
|
|
Turnover (UK) |
- |
- |
- |
1.8 |
2.1 |
|
Turnover (Exports) |
- |
- |
- |
6.5 |
6.1 |
|
Total Turnover |
5.3 |
5.6 |
3.7 |
8.2 |
8.2 |
|
Cost of Sales |
2.3 |
2.7 |
3.3 |
5.8 |
4.4 |
|
Gross Profit |
3.0 |
2.9 |
0.4 |
2.5 |
3.8 |
|
Depreciation |
0.1 |
0.0 |
0.1 |
0.1 |
0.1 |
|
Other Expenses |
2.2 |
2.5 |
3.4 |
3.7 |
2.9 |
|
Operating Profit |
0.8 |
- |
-3.1 |
-1.2 |
0.9 |
|
Other Income |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Interest Paid |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Exceptional Income |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Discontinued Operations |
0.0 |
0.0 |
0.0 |
0.0 |
- |
|
Profit Before Taxes |
0.8 |
0.3 |
-3.1 |
-1.2 |
0.9 |
|
Tax Payable / Credit |
0.0 |
-0.2 |
0.0 |
0.0 |
0.0 |
|
Extraordinary Items/Debits |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Dividends |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Profit After Taxes |
0.8 |
0.5 |
-3.1 |
-1.2 |
0.9 |
|
Minority Interests (Profit & Loss) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Audit Fees |
0.0 |
0.0 |
0.1 |
0.0 |
0.0 |
|
Non Audit Fees |
0.0 |
0.0 |
0.0 |
0.1 |
0.0 |
|
Number of Employees |
32 |
26 |
36 |
42 |
37 |
|
Wages |
1.2 |
1.4 |
1.8 |
1.9 |
1.8 |
|
Social Security Costs |
0.2 |
0.1 |
0.2 |
0.3 |
0.2 |
|
Pensions |
- |
- |
- |
0.0 |
0.0 |
|
Other Pension Costs |
0.0 |
0.0 |
0.1 |
0.1 |
0.1 |
|
Employees Remuneration |
1.4 |
1.6 |
2.0 |
2.2 |
2.1 |
|
Directors Emoluments |
- |
- |
- |
0.1 |
0.1 |
|
Other Costs |
- |
- |
- |
0.0 |
0.0 |
|
Directors Remuneration |
0.2 |
0.1 |
0.1 |
0.1 |
0.1 |
|
Highest Paid Director |
- |
0.1 |
0.1 |
- |
- |
Annual Balance Sheet
Financials
in: USD (mil)
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
31-Dec-2006 |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate |
0.638712 |
0.619253 |
0.695531 |
0.502361 |
0.510947 |
|
Consolidated |
No |
No |
No |
No |
No |
|
|
|
|
|
|
|
|
Land & Buildings |
- |
0.0 |
0.0 |
0.0 |
0.0 |
|
Fixtures & Fittings |
- |
0.0 |
0.0 |
0.0 |
0.0 |
|
Plant & Vehicles |
- |
0.0 |
0.0 |
0.1 |
0.1 |
|
Total Tangible Fixed Assets |
0.3 |
0.0 |
0.0 |
0.1 |
0.1 |
|
Intangible Assets |
0.5 |
0.0 |
0.0 |
0.2 |
0.7 |
|
Investments |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Fixed Assets |
0.7 |
0.0 |
0.0 |
0.3 |
0.8 |
|
Stocks |
1.1 |
1.1 |
1.8 |
3.4 |
2.3 |
|
Work in Progress |
0.2 |
0.6 |
0.0 |
0.1 |
0.1 |
|
Total Stocks Work In Progress |
1.3 |
1.7 |
1.8 |
3.5 |
2.4 |
|
Trade Debtors |
0.8 |
0.6 |
0.2 |
1.3 |
2.1 |
|
Inter-Company Debtors |
0.4 |
0.3 |
0.2 |
0.2 |
0.2 |
|
Director Loans |
0.0 |
0.0 |
- |
- |
- |
|
Other Debtors |
0.1 |
0.1 |
0.1 |
0.4 |
0.3 |
|
Total Debtors |
1.3 |
0.9 |
0.4 |
1.9 |
2.6 |
|
Cash and Equivalents |
0.1 |
0.0 |
0.0 |
0.3 |
0.7 |
|
Other Current Assets |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Current Assets |
2.7 |
2.5 |
2.2 |
5.7 |
5.8 |
|
Total Assets |
3.4 |
2.6 |
2.3 |
6.0 |
6.5 |
|
Trade Creditors |
0.8 |
0.7 |
0.8 |
1.5 |
1.2 |
|
Bank Overdraft |
0.0 |
0.2 |
0.3 |
- |
- |
|
Inter-Company Creditors |
- |
- |
- |
3.2 |
3.1 |
|
Hire Purchase (Current Liability) |
0.0 |
- |
- |
- |
- |
|
Finance Lease (Current Liability) |
0.0 |
- |
- |
- |
- |
|
Total Finance Lease/Hire Purchase (Current Liability) |
0.0 |
- |
- |
- |
- |
|
Accruals/Deferred Income (Current Liability) |
0.2 |
0.3 |
0.3 |
0.6 |
0.5 |
|
Social Security/VAT |
0.1 |
0.3 |
0.2 |
0.2 |
0.1 |
|
Other Current Liabilities |
0.4 |
0.3 |
0.4 |
0.2 |
0.2 |
|
Total Current Liabilities |
1.5 |
1.9 |
2.1 |
5.6 |
5.0 |
|
Group Loans (Long Term Liability) |
2.8 |
2.6 |
2.3 |
0.0 |
0.0 |
|
Director Loans (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Hire Purchase (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Leasing (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Hire Purchase Loans (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Other Long Term Loans |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Accruals/Deferred Income (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Other Long Term Liabilities |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Long Term Liabilities |
2.8 |
2.6 |
2.3 |
0.0 |
0.0 |
|
Deferred Taxation |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Other Provisions |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Provisions |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Issued Capital |
0.8 |
0.8 |
0.8 |
1.0 |
1.0 |
|
Share Premium Accounts |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
|
Revaluation Reserve |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Retained Earnings |
-5.6 |
-6.7 |
-6.4 |
-5.5 |
-4.2 |
|
Other Reserves |
3.7 |
3.8 |
3.4 |
4.6 |
4.6 |
|
Minority Interests (Balance Sheet) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Shareholders Funds |
-0.9 |
-1.9 |
-2.1 |
0.4 |
1.6 |
|
Net Worth |
-1.4 |
-1.9 |
-2.1 |
0.2 |
0.9 |
Annual Cash Flows
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
31-Dec-2006 |
|
Period Length |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate
(Period Average) |
0.647573 |
0.641508 |
0.545576 |
0.499878 |
0.543438 |
|
Consolidated |
No |
No |
No |
No |
No |
Annual Ratios
Financials
in: USD (mil)
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
31-Dec-2006 |
|
Period Length |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate |
0.638712 |
0.619253 |
0.695531 |
0.502361 |
0.510947 |
|
Consolidated |
No |
No |
No |
No |
No |
|
|
|
|
|
|
|
|
Current Ratio |
1.74 |
1.37 |
1.04 |
1.02 |
1.16 |
|
Liquidity Ratio |
0.92 |
0.48 |
0.21 |
0.39 |
0.67 |
|
Stock Turnover |
4.25 |
3.52 |
1.66 |
2.32 |
3.58 |
|
Credit Period (Days) |
53.38 |
35.96 |
23.37 |
58.63 |
87.77 |
|
Working Capital by Sales |
21.13% |
11.74% |
3.17% |
1.56% |
8.97% |
|
Trade Credit by Debtors |
1.04 |
1.28 |
4.35 |
1.11 |
0.55 |
|
Return on Capital |
41.89% |
48.83% |
-1,825.62% |
-296.23% |
61.71% |
|
Return on Assets |
22.91% |
13.40% |
-107.80% |
-20.00% |
14.89% |
|
Profit Margin |
14.44% |
5.89% |
-82.82% |
-14.64% |
11.17% |
|
Return on Shareholders Funds |
- |
- |
- |
-296.23% |
61.71% |
|
Borrowing Ratio |
-200.69% |
-147.14% |
-122.54% |
1,272.85% |
336.70% |
|
Equity Gearing |
-27.73% |
-72.96% |
-94.79% |
6.75% |
24.13% |
|
Debt Gearing |
-199.76% |
-137.61% |
-106.23% |
- |
- |
|
Interest Coverage |
61.59 |
22.18 |
-80.47 |
-303.00 |
117.97 |
|
Sales by Tangible Assets |
20.80 |
309.11 |
73.25 |
68.14 |
69.44 |
|
Average Remuneration per Employee |
0.0 |
0.1 |
0.0 |
0.1 |
0.1 |
|
Profit per Employee |
0.0 |
0.0 |
-0.1 |
0.0 |
0.0 |
|
Sales per Employee |
0.2 |
0.2 |
0.1 |
0.2 |
0.2 |
|
Capital Employed per Employee |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Tangible Assets per Employee |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Assets per Employee |
0.1 |
0.1 |
0.1 |
0.1 |
0.2 |
|
Employee Remuneration by Sales |
25.74% |
28.96% |
54.22% |
26.86% |
25.21% |
|
Creditor Days (Cost of Sales Based) |
128.38 |
94.84 |
113.51 |
92.32 |
90.74 |
|
Creditor Days (Sales Based) |
55.49 |
46.05 |
101.69 |
64.88 |
48.30 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.18 |
|
UK Pound |
1 |
Rs.76.65 |
|
Euro |
1 |
Rs.66.63 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.